With whom does the French drug industry want to work for phase I?
Industry chooses phase I partners by evaluating quality versus cost. However, since December 20, 1988, in France only those centers, private or public, authorized by the French authorities can be chosen. However, ability to perform rapidly, reliability and worldwide acceptability of results will be considered in choosing the phase I partner.
Bogaievsky
Y
Y
Institut de Recherche Jouveinal, Fresnes, France.
D004341:Drug Evaluation / Q000191:economics / Q000639:trends*; D004345:Drug Industry / Q000639:trends*; D005602:France; D006801:Humans; D007880:Legislation, Drug / Q000639:trends*